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Effects of Sirolimus on Lung function in patients with 
Lymphangioleiomyomatosis 
 
 
Abstract 
Background: Lymphangioleiomyomatosis (LAM) is a progressive lungs disease that 
affects women at reproductive years. Sirolimus inhibits mammalian target of rapamycin 
(mTOR) and its administration in past studies was hopeful in treatment of patients with LAM. 
The aim of this study was to evaluate sirolimus therapy on lung function in LAM patients. 
Methods: We conducted a trial to evaluate the effect of sirolimus on six patients with 
LAM who had severe or very severe obstructive lung disease, and one-year follow up. 
Maintenance level of Sirolimus was 10-15 ng/ml. Serial visits (including physical 
examination, evaluation of signs and symptoms of disease and adverse events due to 
treatment), spirometry, 6MWT done at baseline 3, 6, 9 and 12 months after. Spirometric 
parameters walk distance and O2 saturationbefore and after exercise at first and the end of 
treatment were measured. 
Results: Four patients had TSC-LAM while the other 2 patients had S-LAM. The mean 
level of sirolimus was 13 ng/ml after one-year treatment. Mean FEV1 at enrollment and 
end of study was 1000cc (33% predict) and 1228cc (42% predict) respectively (P=0.674). 
The mean FVC at baseline and end of study was 1648cc (49% predict) and 1866cc (55% 
predict) (P=0.996). The mean FEV1/FVC at enrollment and the end of treatment was 58% 
and 62% respectively (P=0.753). The mean FEF25-75 at first and at the end of treatment 
was 16% and 26%, respectively (P=0.028). The mean walk distance in 6MWT at first and 
at the end of study was 315 meters (P=0.9). The mean percentage of O2 saturation at rest 
was 84% and 92% at first and at the end of study (P=0.104). 
Conclusion: In LAM patients, sirolimus has been shown stabilizeto or improve lung 
function, rest and exertional O2 saturation. Sirolimus was effective in LAM patients who 
had severe or very severe physiological disorders. 
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Lymphangioleiomyomatosis (LAM) is an uncommon neoplastic and systemic 
disease. LAM occurs sporadically (S-LAM) or with tuberous sclerosis complex (TSC–
LAM) (1).  
It is associated with lung cystic destruction, recurrent pneumothoraces, abdominal 
tumors and chylous effusions in thorax and abdomen (2, 3). LAM affects young women 
almost exclusively in reproductive years. LAM involves all races. Prevalence of disease is 
2.5 per million. Prevalence of tuberous sclerosis complex is 40 per million. Respiratory 
manifestations occur in 5 to 20% of patients with TSC. The TSC-LAM is 10 times more 
prevalent than S-LAM (1, 4).  Sirolimus in rodent models of TSC made neoplastic growth 
regression in the liver and kidney (4-6). 
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Sirolimus blocks hyperphosphorylation of s6 resulting in 
regular cell growth. Sirolimus side effects are oral aphthous, 
hypercholesterolemia, pneumonia, diarrhea, cellulitis, 
pyelonephritis, headache, palpitation, mucositis and etc (2-
11). The aim of this study was to evaluate sirolimus therapy 
on lung function in LAM patients. 
 
 
Methods 
We conducted a before-after clinical trial of sirolimus on 
8 LAM patients in Masih Daneshvari Hospital, Tehran. The 
study samples were rapid progressive S-LAM or TSC-LAM. 
Patient’s diagnosis was on the basis of biopsy, clinical 
findings, HRCT and TSC presentation. The patients with 
each of the following criteria were excluded: current or 
planned pregnancy, breast feeding, plural effusion, cardio-
pulmonary transplantation, liver dysfunction (AST or 
ALT>150u/l, Albumin>150 g/lit), hematologic dysfunction 
(HCT<30%, plt<10000/mm, neutrophil<1500/cc, 
WBC<3000/mm), renal hemorrhage in past year, 
proteinuria> 1gr/24hrs, recurrent infection, current surgery in 
past 2 months, known as sirolimus allergy, 
creatinine>2.5mgr/dlit, malignancy or stroke or myocardial 
infarction history, estrogen medication and a patient who 
was not able to do pulmonary function test (PFT) or six-
minute walk test (6MWT). Although LAM cases are rare, we 
used convenient non-randomized sampling and to increase 
the power of the study, before-after method was performed. 
Informed consent was obtained from each subject and 
sirolimus adverse effects were explained to each patient. The 
study was approved by the Medical Ethics of Shahid 
Beheshti University of Medical Sciences.   
Sirolimus therapy and follow up: The target sirolimus 
blood level of 10-15 ng/ml, and 12 months follow-up was 
considered. Oral 2mg sirolimus was administered and 
follow-up visits were conducted every three months. The 
following assessment was done in every visit: PFT including 
statistic, dynamic, volume and flows and FEV1/FVC, FEV, 
FVC, FEF25%-75%. The distance covered in the 6MWT: 
the distance and O2 saturation at the baseline and the end of 
study was checked. Clinical presentation such as cough, 
chest pain, dyspnea, pneumothorax, chilothorax, medication 
side effects, lipid profile and complete blood count (CBC) 
were checked. 
Statistical analysis: Statistical analyses were done by SPSS 
Version.19). The LAM patients’ improvement was defined 
as the mean differences of FEV1, FVC, FEV1/FVC, 
FEF25%-75%, distance and O2 saturation in 6MWT before 
and after sirolimus treatment. The non-parametric paired t-
test (Wilcoxon rank test) was used. Because of limited 
sample size (8 patients) and non-symmetric distribution, data 
were presented as mean ± standard error of mean (SEM) and 
range (min-max).  
 
 
Results 
A total of 8 LAM patients (4 TSC-LAM and 4 S-LAM) 
were eligible for the study. Five patients were diagnosed 
based on biopsy (3 open biopsy and 2 TBLB) and 3 patients 
on CT-scan and TSC presentation. One of the cases died 
while the other underwent lung transplantation. Finally 6 
patients completed the study with 12 months follow up. The 
mean age of patients was 34.21 years old (range: 26-50). 
Pneumothorax was the primary event leading to diagnosis in 
2(33%) cases, cough and dyspnea in 4(67%) patients. All 
cases were treated with medroxy-progesterone and 
bronchodilators. None of them were smokers. The patient's 
PFT at the enrollment was severe obstructive in 4 cases and 
very severe obstructive in 2 cases. The blood mean level of 
sirolimus was 13 ng/dl. The impact of sirolimus on PFT, 
6MWT distance and O2 saturation was illustrated in tables  
1-2.  
Table 1. Pulmonary function test and 6 minute walk distance characteristics in 6 LAM patients before and after sirolimus treatment 
PFT/6MWT Baseline After 12 months Mean ± SEM (range) P-value Power 
FEV1/FVC (%) 58 ( 35-83) 62 (42-74) 4±19 0.753 0.19 
FEV1 (%) 33 (16-58) 42 (14-75) 9±17 0.674 0.18 
Mean FEV1 (cc) 1000  1228 228±471 0.753 0.25 
FVC (%) 49 55 6±24 0.916 0.22 
Mean FVC (cc) 1648 1866 218±785 0.917 0.23 
FEF 25%-75% (%) 16 26 10±24 0.028 0.7 
Mean of distance 6MWT 305 (234-398) 315 10 0.9 0.76 
O2 saturation in start of 6MWT (%) 84 92 8±11 0.104 0.57 
O2 saturation at the end of 6MWT (%) 74 79 5±10 0.272 0.39 
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Table 2. Pulmonary function test and 6-minute walk distance characteristics in 6 LAM patients during 12 month sirolimus 
treatment 
PFT/6MWT Baseline 
After 3 
months 
After 6 
months 
After 9 
months 
After 12 
months 
p-
value 
FEV1/FVC 0.33±0.167 0.583±0.131 0.598±0.109 0.615±0.111 0.625±0.110 0.753 
FEV1 0.336±0.167 0.365±0.191 0.408±0.217 0.428±0.111 0.625±0.110 0.674 
Mean FEV1 1000±516.2 1133.3±637.6 1047±594.7 1236.6±697.8 1228.3±771.3 0.753 
FVC 1648.3±547.8 1841.6±696.9 1743.3±709.6 1833.3±785.3 1866.6±919.6 0.916 
FEF 25%-75% 0.165±0.102 0.201±0.13 0.196±0.117 0.191±0.076 0.26±0.165 0.028 
Mean of distance 6MWT 305±68.84 292.5±135.09 343.33±124.17 369.16±139.67 315.16±130.57 0.9 
O2 saturation in start of 
6MWT 
0.843±0.11 0.863±0.07 0.886±0.04 0.871±0.06 0.928±0.02 0.104 
O2 saturation at the end of 
6MWT 
0.745±0.14 0.768±0.13 0.775±0.085 0.783±0.10 0.79±0.116 0.272 
 
Also, the improvement pattern of PFT was shown in 
figure 1. Cough and dyspnea improved clinically in all 
patients. Adverse events occurred as follows: Aphthous ulcer 
in 3 cases, peripheral edema in 1 case, headache in 2 cases 
and oral abscess in 1 case. Respiratory infections and 
sirolimus pneumonitis were not reported. One of the six 
patients stopped sirolimus treatment after 12-month follow-
up period because of recurrent headache. 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Pulmonary function test improvement during 
12 months 
 
Discussion 
In our study, the mean of FEV1 and FVC increased by 
228cc and 218cc after one-year treatment with sirolimus, 
respectively. The mean FEV1 and FVC at baseline were 1li 
(33% pred) and 1.648li (49% pred), respectively. Two 
patients were diagnosed with severe obstructive disease and 
four patients had severe obstructive disease. In a study by 
Neurohr et al. in 2011 on 10 female patients with LAM, the 
mean gain of FEV1 and FVC was 345cc and 448cc after 6 
months treatment with sirolimus. The mean FEV1 and FVC 
at baseline were 36% pred and 69% pred, respectively. The 
maintenance level of sirolimus was 5-10 ng/ml in their study 
(9). In a study conducted by McCormack et al. in 2011, the 
mean gain of FEV1 and FVC was 153cc and 226cc after 12 
months of treatment, respectively (8). Their trial involved 89 
patients with LAM who had moderate lung impairment and 
sirolimus levels in the active –treatment group were 
maintained between 5 and 15ng per milliliter. Maintenance 
level of sirolimus in our study is in line with two other 
studies. Our study patients had more severity of pulmonary 
dysfunction and our finding demonstrated a comparable gain 
of FEV1 and FVC with other studies. However, because of 
the small sample size in our work, the sirolimus effect was 
not statistically significant .Another possible explanation for 
the lack of a significant effect of sirolimus may be the 
severity of disease in the studied patients. 
In our study, 50% of patients had FEV1 values above 
baseline and 33% of patients had FVC values above baseline 
values. Frequency of patients with FEV1 values above 
baseline in our study is comparable with the study of 
McCormack et al. (50% vs. 46%). Frequency of patients 
with FVC values above baseline in McCormack et al. (8) 
study was 54% that is more than our study that may be 
explained with severity of disease in our patients. Our 
findings suggested that sirolimus may be useful in patients 
with LAM and severe pulmonary dysfunction. Patients of 
our study revealed a modest increase in 6MWT at 12 months 
that was not statistically significant. 
In the study of Neurohr et al. (9), however, increase in 
6MWT at 6 months was 49 meters but was not significant 
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because increasing of distance in 6MWT up to 50 meters 
increase in 6MWT is considered as normal. So, this value in 
McCormack et al.’s study was not significant as well. As the 
strength of our study, we recorded O2sat at baseline and after 
6MWT, revealed 8% and 5% gain at the end of treatment. It 
may be related to the improvement of air flow and V/Q 
matching during walking that leads to better exertional 
activity of patients. FEF 25-75% as a measure for evaluating 
of small airway function was recorded in our study after one 
year treatment with sirolimus that revealed a significant 
increase as compared with baseline value. This value is not 
recorded in other studies. Effects of sirolimus on smooth 
muscles of small airways lead to significant improvement of 
air flow. 
In conclusions the present study demonstrated that 
sirolimus administration in Iranian patients with LAM can 
improve FEV1, FVC and oxygenation. Nevertheless, this 
improvement is not statistically significant. Future studies 
with large sample sizes are recommended to better clarify the 
effect of sirolimus on LAM. Nonetheless, sirolimus 
improved air flow of Iranian patients with LAM, it is better 
that these results be confirmed by a more sensitive test e.g. 
cardiopulmonary exercise test (CPET). Furthermore, 
sirolimus is relatively safe in Iranian patients with LAM. 
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